Romidepsin

Hemoglobin SC

Tami D. JohnSmall moleculePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Hemoglobin SC cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2	CCC
Busulphan Tami D. John	Phase 2	CCC
Mesna Tami D. John	N/A	D
Cyclophosphamide Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	N/A	D
Campath 1H Tami D. John	N/A	D

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant

BBB

Indicative ·

76 / 100

Recurrent Mycosis Fungoides/Sezary SyndromeDormant

BBB

Indicative ·

75 / 100

Multiple Myeloma and Plasma Cell NeoplasmDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.